Zevra Therapeutics, Inc. ZVRA Current portion of discount and rebate liabilities

Current portion of discount and rebate liabilities at other companies

XER

Xeris Biopharma Holdings, Inc.XERS

$45.49M+48.0%

WD-40 CompanyWDFC

$11.8M-20.3%

Collegium Pharmaceutical, Inc.COLL

$317.69M-2.1%

Matthews InternationalMATW

$14.54M-19.9%

FMC CorporationFMC

$480M-15.8%

Indivior Pharmaceuticals, Inc. INDV

$551M-18.4%

Other financials

Income statement

See full

Revenue$36.2M+77.5%

Gross profit$34.3M+80.1%

Operating income$52.1M+1,073%

Net income$37.9M+1,323%

EPS (diluted)$0.60+1,100%

Balance sheet

See full

Cash & equivalents$95.6M+156%

Total debt$1.1M-98.1%

Total equity$205.8M+402%

Total assets$278.6M+61.3%

Cash flow

See full

Operating cash flow$6.1M+175%

CapEx$35.0K-64.6%

Free cash flow$6.1M+173%

Valuation

See full

Market cap$782.09M+58.2%

Enterprise value$687.64M+32.5%

P/E6.3×—

P/S6.4×-5.8×

Profitability

See full

Gross margin86.1%+7.2pp

Operating margin-103.9%-43.0pp

Net margin101.6%+60.1pp

FCF margin-75%-30.5pp

Returns & leverage

See full

Return on equity100.7%+60.3pp

Debt / equity0×-1.5×

Current ratio4.9×+1.9×

Where this comes from

Reported directly by Zevra Therapeutics, Inc. in its filing.

Tagged under the XBRL concept zvra:DiscountAndRebateLiabilityCurrent.

The official record: Zevra Therapeutics, Inc.’s 10-K, filed March 9, 2026, on SEC EDGAR. View the filing →

Ask your AI about Zevra Therapeutics, Inc.'s current portion of discount and rebate liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Zevra Therapeutics, Inc.'s current portion of discount and rebate liabilities?: Zevra Therapeutics, Inc. (ZVRA) reported current portion of discount and rebate liabilities of $12.19M in Q4 2025.
What does current portion of discount and rebate liabilities mean?: This represents the estimated financial obligation for expected discounts, rebates, and chargebacks owed to wholesalers, distributors, or government programs that are expected to be settled within one year. It reflects the company's short-term liability related to commercial product pricing adjustments and contractual sales incentives. Monitoring this balance is essential for understanding the impact of gross-to-net revenue adjustments on near-term cash flow.